##semicolon##
SCN8A; developmental and epileptic encephalopathy; hypsarrhythmia; early-onset epilepsy; whole-exome sequencing.##submission.citations##
1. Bunton-Stasyshyn RKA, Wagnon JL, Wengert ER, et al. Prominent role of forebrain excitatory neurons in SCN8A encephalopathy. Brain. 2019;142(2):362–375. doi:10.1093/ brain/awy324.
2. Catterall WA. Voltage-gated sodium channels at 60: structure, function and pathophysiology. J Physiol.2012; 590 (11):2577–2589. doi:10.1113/jphysiol.2011.224204.
3. Conecker G, Xia MY, Hecker J, et al. Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A-related epilepsy and/or neurodevelopmental disorders. Epilepsia. 2024. doi:10.1111/epi.17992.
4. Gardella E, Marini C, Trivisano M, et al. The phenotype of SCN8A developmental and epileptic encephalopathy. Neurology. 2018;91(12):e1112–e1124. doi:10.1212/WNL.00000000 00006199.
5. Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology. 2015; 84(5):480–489. doi:10.1212/WNL.0000000000001211.
6. Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology. 2015;84(5): 480–489. doi:10.1212/WNL.0000000000001211.
7. Liu Y, Schubert J, Sonnenberg L, et al. Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability. Brain. 2019;142(2):376–390. doi:10.1093/brain/awy326.
8. Liu Y, Schubert J, Sonnenberg L, et al. Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability. Brain. 2019;142(2):376–390. doi:10.1093/brain/awy326.
9. Meisler MH, Hill SF, Yu W. Sodium channelopathies in neurodevelopmental disorders. Nat Rev Neurosci. 2021;22(3):152–166. doi:10.1038/s41583-020-00414-9.
10. Oikawa S, et al. Treatment Options for Infantile Spasms Syndrome with SCN8A: A Case Report and Literature Review. 2024. doi:10.1055/s-0043-1778011.
11. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30.
12. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–521. doi:10.1111/epi.13709.
13. Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019;142(8): 2303–2318. doi:10.1093/brain/awz195.
14. Talwar D, Hammer MF. SCN8A Epilepsy, Developmental Encephalopathy, and Related Disorders. Pediatr Neurol. 2021.
15. Wagnon JL, Meisler MH. Recurrent and non-recurrent SCN8A mutations: clinical and mechanistic implications. Brain.2015;138(Pt 7):1939–1952. doi:10.1093/brain/awv134.
16. Wengert ER, et al. Prax330 reduces persistent and resurgent sodium channel currents and protects against seizures in a model of SCN8A epileptic encephalopathy. 2019.
17. Zaman T, Helbig I, Boelman C, et al. SCN8A-associated developmental and epileptic encephalopathy: a multi-center cohort study. Brain. 2020;143(1):131–145. doi:10.1093/brain/ awz337.